This is therefore a contrasting of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Acasti Pharma Inc. (NASDAQ:ACST) and Immunic Inc. (NASDAQ:IMUX). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acasti Pharma Inc. | 1 | 0.00 | N/A | -1.22 | 0.00 |
| Immunic Inc. | 13 | 0.00 | N/A | -34.26 | 0.00 |
In table 1 we can see Acasti Pharma Inc. and Immunic Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 shows the net margins, return on assets and return on equity of the two firms.
| Net Margins | Return on Equity | Return on Assets | |
| Acasti Pharma Inc. | 0.00% | 0% | 0% |
| Immunic Inc. | 0.00% | -235.3% | -182.3% |
Analyst Recommendations
Acasti Pharma Inc. and Immunic Inc. Recommendations and Ratings are available on the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Acasti Pharma Inc. | 0 | 0 | 1 | 3.00 |
| Immunic Inc. | 0 | 0 | 1 | 3.00 |
The consensus target price of Acasti Pharma Inc. is $7.75, with potential upside of 262.15%. On the other hand, Immunic Inc.’s potential upside is 178.36% and its consensus target price is $40. Based on the analysts view we can conclude, Acasti Pharma Inc. is looking more favorable than Immunic Inc.
Institutional and Insider Ownership
Institutional investors owned 4.02% of Acasti Pharma Inc. shares and 1.6% of Immunic Inc. shares. Acasti Pharma Inc.’s share owned by insiders are 13.28%. On the other hand, insiders owned about 0.3% of Immunic Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Acasti Pharma Inc. | 2.99% | 107.76% | 181.87% | 129.52% | 338.18% | 189.7% |
| Immunic Inc. | 1.94% | 21.1% | 2.94% | 71.52% | -95.65% | 83.31% |
For the past year Acasti Pharma Inc. was more bullish than Immunic Inc.
Summary
Acasti Pharma Inc. beats on 5 of the 7 factors Immunic Inc.
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
